Gut bacteria boosts immunotherapy in stubborn lung cancer?
NCT ID NCT06448572
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This study tests whether adding a healthy gut bacteria (EXL01) to the immunotherapy drug nivolumab can help control advanced non-small cell lung cancer that has stopped responding to standard treatments. About 21 adults whose cancer progressed after prior therapies will receive the combination. The goal is to see if the bacteria can make the immunotherapy work better again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Lille
RECRUITINGLille, 59000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.